EMA · European Union
rosiglitazone — EMA regulatory status
rosiglitazone (AVANDAMET) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA unknown.
Status snapshot
- Status
- EMA unknown
- Brand
- AVANDAMET
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
- Target
- Peroxisome proliferator-activated receptor gamma
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Peroxisome proliferator-activated receptor gamma agonist. Target: Peroxisome proliferator-activated receptor gamma. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: unknown.
Linked evidence on this spoke: 2 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | unknown | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Rosiglitazone Extended Release 2mg | Phase 3 | GSK Glaxo Smith | NCT00348140 |
| rosiglitazone | Phase 3 | Novo Nordisk A/S | NCT00343980 |
Related hubs
FAQ
What is the EMA approval status of rosiglitazone?
rosiglitazone currently shows EMA unknown in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get rosiglitazone regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to rosiglitazone?
This spoke lists 2 published programs associated with rosiglitazone in our pipeline index.